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A key task for health policymakers is to optimise the outcome of health care interventions. The pricing of a new generation of cancer
drugs, in combination with limited health care resources, has highlighted the need for improved methodology to estimate outcomes
of different treatment options. Here we introduce new general methodology, which for the first time employs continuous hazard
functions for analysis of survival data. Access to continuous hazard functions allows more precise estimations of survival outcomes for
different treatment options. We illustrate the methodology by calculating outcomes for adjuvant treatment of gastrointestinal stromal
tumours with imatinib mesylate, which selectively inhibits the activity of a cancer-causing enzyme and is a hallmark representative for
the new generation of cancer drugs. The calculations reveal that optimal drug pricing can generate all win situations that improve drug
availability to patients, make the most of public expenditure on drugs and increase pharmaceutical company gross profits. The use
of continuous hazard functions for analysis of survival data may reduce uncertainty in health care resource allocation, and the
methodology can be used for drug price negotiations and to investigate health care intervention thresholds. Health policy makers,
pharmaceutical industry, reimbursement authorities and insurance companies, as well as clinicians and patient organisations, should
find the methodology useful.
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Cancer includes a wide spectrum of diseases that place a massive
economic burden on society. It is currently estimated that one in
three will be diagnosed with cancer at some time in life, that one in
four will die from cancer and, although cancer diseases are more
common among the elderly, their relative contribution to disability
and death in younger people remains high (Boyle and Ferlay, 2005;
Danaei et al, 2005; Ries et al, 2005).
All forms of cancer have two features in common; alterations to
the genetic code and unrestricted cell growth, the latter being a
consequence of the former. Since the latter also constitutes the
point of attack for the vast majority of current cancer therapies,
normal cells are essentially affected in the same way as cancer cells.
This makes precise dosage very difficult and calls for development
of more specific therapies.
The recent completion of the human genome project (Lander et al,
2001) has prompted a paradigm shift towards medicine characterised
less by treating symptoms and more by looking to the fundamental
causes of disease. Detailed knowledge about the molecular origins of
disease now allows rational drug design. A new generation of cancer
drugs, which selectively inhibits the activity of cancer-causing genes
or their protein products, is just reaching the market, but recent
reports question the pricing and availability of new cancer drugs
(Berenson, 2005; Goldman, 2005; Smith, 2005; Wilking and Jonsson,
2005) and have highlighted a need for improved methodology to
estimate benefits of health care interventions.
A general method to estimate benefits of health care interven-
tions is to predict the expected gain in quality adjusted life years
(QALYs) (Drummond et al, 1997), which take into account both
quantity and quality of life generated by health care interventions.
QALYs provide a common currency to assess the extent of the
benefits gained from a variety of interventions in terms of health
related quality of life and survival for the patient. When combined
with the cost for providing the interventions, cost–utility ratios
result. These indicate the additional cost to generate a year of
perfect health (one QALY). Comparisons can be made between
interventions, and priorities can be established based on those
interventions that are relatively inexpensive (low cost per QALY)
and those that are relatively expensive (high cost per QALY). The
use of QALYs in resource allocation decisions thus means that
choices between different patient groups competing for medical
care are made explicit and health care policymakers are given an
insight into the likely benefits from investing in new technologies
and therapies. A key question is whether the expected gain in
QALYs outweighs the costs associated with the development of
more specific treatments. QALYs are nonetheless far from perfect
as a measure of outcomes, with a number of technical and
methodological shortcomings. Improvements in disease manage-
ment hence call for better methods to predict the expected gain in
QALYs.
Survival data are commonly analysed by Cox regression (or
proportional hazards regression), and results are often presented
as simple hazard ratios. Distinct limitations of this methodology
are that the resulting hazard functions are discontinuous, that the
influence of time will not be explicitly modelled and that the
hazard ratios are assumed to be constant over time. However,
multidimensional hazard functions can be determined in a way
that they are continuous in all time variables. Here we introduce
the use of continuous hazard functions for QALY calculations.
We show that special Poisson regression models allow hazard
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sfunctions to be estimated as continuous functions, which makes it
possible to derive and calculate probabilities, expected length of
life and expected gain in QALYs.
An urgent question for health policymakers is whether the new
generation of cancer drugs will provide value for money in
comparison to other health care interventions. Gastrointestinal
stromal tumours (GISTs) are non-epithelial tumours of the
gastrointestinal tract that are commonly caused by activating or
gain-of-function mutations in the KIT gene (Hirota et al, 1998). If
surgery failed, GISTs were inevitably fatal until the discovery of the
tyrosine kinase inhibitor imatinib mesylate (Gleevec
s) (Buchdun-
ger et al, 1996; Joensuu et al, 2001; Tuveson et al, 2001). Imatinib
mesylate reduces GIST cell proliferation by binding to the catalytic
pocket of the KIT protein product (Schindler et al, 2000), and
serves as a hallmark representative for the emerging generation of
cancer drugs that selectively inhibits the activity of cancer causing
genes or their protein products. We illustrate the new methodology
by calculating the expected gain in QALYs for adjuvant treatment
of GIST patients with imatinib mesylate.
PATIENTS AND METHODS
Methodology for GIST data collection and analysis has been
described in detail elsewhere (Nilsson et al, 2005). In essence, a
retrospective (1983–2000) population-based study revealed that
for GIST patients who initially undergo complete tumour removal
by surgery (R0 resection), tumour recurrence correlates with the
following prognostic factors: age, tumour size, time since surgery
for GIST, Ki67 max% (immunohistochemical measure of pro-
liferative index using monoclonal KIT antibody Ki-67) and
deletion of exon 11 of the KIT gene.
Quality adjusted life years are the arithmetic product of life
expectancy and a measure of the quality of the remaining life years,
and place a weight on different health states. One year of perfect
health is worth 1 QALY, and a year of less than perfect health life
expectancy is worth less than 1 QALY. Death is considered to be
equivalent to 0. Age- and sex-dependent QALY values are available in
5-year intervals (Kind, 1996): QALY values equal 1 per year for ages
up to 50 years, and then successively decline with age to 0.76 and 0.67
QALY per year for 85-year-old men and women respectively.
Similarly, QALY decreases are expected for GIST patients who suffer
tumour recurrence. Additional treatment costs relating to tumour
recurrence can be calculated separately from QALY. Albeit, here we
make the assumption that the extra cost per day relating to tumour
recurrence is a certain fixed proportion of the QALY generating cost
for a GIST patient who has not suffered tumour recurrence at the
same age. Consequently, the QALY function q is stepwise constant in
5-year intervals in our calculations, and the QALY value for an
individual from age a to age b is defined as
Qða; bÞ¼
Zb
a
qðtÞdt
If we take into account a possible QALY decrease following tumour
recurrence at age c to a proportion r, and also include a discount of
p%, the QALY is calculated as
Qða; b; c; r; pÞ¼
Zc
a
qðtÞexpð logðð1 þ p=100ÞÞðt   aÞÞdt
þ r
Zb
c
qðtÞexpð logðð1 þ p=100ÞÞðt   aÞÞdt
For GIST patients who have not suffered tumour recurrence at age b,
the corresponding QALY equals Q(a,b,b,r,p),t h a ti s ,c¼b. The
constant r is a merger that accounts for treatment side effects,
reductions in health-related quality of life, and treatment costs
following tumour recurrence at c (see Supplementary Information
for details). Here we assume a 20% QALY decrease (r¼0.80)
following tumour recurrence at c.
Our main objective was to establish general methodology that
permits more precise QALY calculations. Here we adapt the
methodology to calculate the expected gain in QALYs for GIST
patients following 1 year of adjuvant treatment with imatinib
mesylate. To describe the instant rates of certain events, we define
four hazard functions. The first, denoted hrþd, represents the
combined event of detection of tumour recurrence, including local
recurrence or metastases, or death before detection of tumour
recurrence. This hazard function can be approximated by the sum
of two separate hazard functions, hr, which represents detection of
tumour recurrence, and hd, which represents death before
detection of tumour recurrence. The hr hazard function was
estimated as a function of the prognostic factors for GIST listed
above: current age, tumour size, time since surgery, Ki67 max%
and the zero-or-one variable ‘KIT exon 11 deletion’. The hd hazard
function, representing death before detection of tumour recur-
rence, was estimated to be 8% above the death rate of the general
population, and was put to 1.08 times the death rate of the general
population. A fourth hazard function, denoted hdar, represents
death after detection of tumour recurrence. Finally, the hazard
function representing death among the general population was
calculated from data available from Statistics Sweden
(www.scb.se). All hazard functions are of the form ex-
p(b0þb1x1þyþbkxk), where the b’s are coefficients and
x1,y, xk are the values of the variables, and were estimated by
Poisson regression (Breslow and Day, 1987). A detailed derivation
of the formula for QALY calculations using the hazard functions is
available as Supplementary Information.
RESULTS
Four hazard functions were considered to calculate the QALY
gains resulting from adjuvant treatment of GIST patients
with imantinib mesylate. Tables 1 and 2 and Supplementary
Information Table I list the b-coefficients that define the hazard
functions.
The variables Ki67 max%, tumour size and deletion of KIT exon
11 allow us to formulate a risk score for tumour recurrence, which
equals the linear combination of the three variables with the
weighted b-coefficients (Table 1). The estimated gradient of risk
per 1 s.d. of the score is 4.21. This means that if two patients have
risk scores that differ by 1 s.d., the patient with the higher score
has 4.21 times higher risk of tumour recurrence than the patient
with the lower score. Gradient of risk per 1 s.d. is a notion
introduced to describe and compare the predictive power of a
single variable or a score based on several variables. The gradient
of risk, for example, of bone mineral density measured in the hip
to predict hip fracture is 2.6 (Marshall et al, 1996). The risk of
death without or before detection of tumour recurrence does not
deviate significantly from the risk of death for the general
population. The hazard ratio vs the general population is 1.08
(95%, confidence interval 0.89–1.36), whereas the risk of death
after detection of tumour recurrence is substantially higher
(Table 2).
The death hazard function depicted in Figure 1 is an example
that has been calculated from Tables 1 and 2, and the death hazard
of the general population (Supplementary Information Table I).
It shows how the risk of death changes for a 65-year-old man
who undergoes surgery for GIST, and is diagnosed with tumour
recurrence 1 year after the surgery. According to the above, his
risk of death is very close to the risk of death for the general
population before detection of tumour recurrence. In contrast,
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sthe risk of death increases dramatically following tumour
recurrence.
Table 3 illustrates the expected QALY gains, adjusted for
treatment costs following recurrence, resulting from administra-
tion of imatinib mesylate for four different GIST patients. The
calculations reveal that treatment with imatinib mesylate results
in considerably higher expected QALY gains for patients A and B
than for patients C and D. The QALY gain exceeds 1 for patients A
and B, while it is a moderate 0.25 and 0.20 for patients C and D
(Table 3, yellow row). The calculations also reveal that larger
QALY gains are accompanied by greatly reduced probability of
death (Table 3, orange rows). The probability of death is reduced
from 47.6 to 10% for patient B, who exhibits the highest calculated
QALY gain (2.16), whereas the probability of death is reduced from
8.1 to 3.9% for patient D, who has a lower calculated QALY gain
(0.20).
Expected QALY gains between 0.5 and 1.0 constitute typical
limits for health care interventions in many Western countries,
when the treatment cost to achieve the gain is in the interval US$
40000–80000. We calculated the expected QALY gain for the GIST
patients comprising the material in 0.5 year increments starting at
the time of surgery. Only patients who were alive, and without
detected tumour recurrence at the starting point, contributed to
the calculation. The number of GIST patients with QALY gain
limits above 1.00, 0.67 and 0.50 are listed in Table 4.
Only patients who were alive, and without detected tumour
recurrence within the specified period after surgery, are available
for adjuvant treatment. Assuming current health care legislation
accepts treatment costs up to US$ 60000 per 1 QALY gained, and
that the actual cost for the treatment is 40000, results in a QALY
gain limit of 0.67 (40000 out of 60000). Table 4 shows that 11
patients are above a QALY gain limit of 0.67 two years after
surgery. The total treatment cost then amounts to US$ 440000
(11 US$ 40000). If the pharmaceutical company providing the
drug would accept a lower price of US$ 30000, the QALY gain limit
decreases to 0.50 (30000 out of 60000). Table 4 shows that 17
patients are above a QALY gain limit of 0.50 two years after
Table 3 Ten-year prospective QALY gain calculations for four GIST
patients that underwent R0 tumour resection 2 years ago
Patient
Variable A B C D
Age at 2 years after surgery 57 62 55 48
Sex Man Woman Woman Man
Ki67 max% 10 20 0.5 1
Tumour size (cm) 6 4.5 4 1.5
KIT exon 11 deletion Yes yes yes yes
Expected QALY 10 years, with
imatinib
6.33 6.51 6.71 7.14
E1 QALY if tumour recurrence
followed by death
a
0.69 1.14 0.14 0.15
E2 QALY if death without
tumour recurrence
0.32 0.19 0.19 0.17
E3 QALY if tumour recurrence
without death
a
0.19 0.88 0.19 0.09
E4 QALY if no tumour
recurrence and no death
4.10 2.14 5.94 6.53
S¼E1+E2+E3+E4, without
imatinib
5.30 4.35 6.46 6.94
QALY gain ¼ With (R)
minus without imatinib
1.03 2.16 0.25 0.20
10-year probability of death,
with imatinib
0.109 0.104 0.050 0.039
10-year probability of death,
patient without imatinib
0.333 0.476 0.092 0.081
GIST¼gastrointestinal stromal tumours; QALY¼quality-adjusted life years. Rows
highlighted in blue list the prognostic factors of importance for risk of tumour
recurrence and/or death. Age- and sex-dependent QALY values of the general
population are highlighted in green and QALY values calculated by the four hazard
functions in grey. The risk of death for GIST patients on imatinib mesylate does not
differ substantially from that of the general population. The QALY of the general
population less the sum of the four hazard functions thus gives the change in QALY
resulting from administration of imatinib mesylate (yellow). Orange rows show that
survival probabilities are highly dependent on imatinib mesylate administration (see
Supplementary Information for details on probability calculations).
aQALY adjusted
for treatment costs following recurrence.
Table 1 b-Coefficients for the hazard function hr, representing detection
of tumour recurrence
Variable b s.e. P-value
Constant  6.2060 1.1495 —
Age 0.0153 0.0152 0.3139
Time since surgery  0.1426 0.0828 0.0851
Ki67 max% 0.1161 0.0148 0.0000
Tumour size 0.1216 0.0194 0.0000
If KIT exon 11 deleted¼1, if not¼0 0.9767 0.3313 0.0032
GIST¼Gastrointestinal stromal tumours. A total of 220 GIST patients who initially
underwent complete tumour removal by surgery (R0 resection) were analysed to
calculate the b-coefficients defining hr. A total of 37 tumour recurrences were
detected in 1305.8 patient years. Standard errors (s.e.) and P-values are listed for
each b-coefficient.
Table 2 b-Coefficients for the hazard function hdar, representing death
after detection of tumour recurrence
Variable b s.e. P-value
Constant  3.21524 1.55063 —
Current age 0.05582 0.02066 0.0069
Sex, man¼0, woman¼1  0.94956 0.40851 0.0201
Min (time since recurrence, 0.5)  2.26048 0.94729 0.0170
Max (time since recurrence,  0.5, 0)  0.11525 0.02982 0.0001
GIST¼Gastrointestinal stromal tumours. The 37 GIST patients who suffered tumour
recurrence after R0 resection (see Table 1 legend) were analysed to calculate the
b-coefficients defining hdar. Among these 37 GIST patients, a total of 33 deaths
occurred in 150.7 patient years. Standard errors (s.e.) and P-values are listed for each
b-coefficient.
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Figure 1 Illustration of the death hazard function and its dependence on
tumour recurrence for GIST patients. In this example, a 65-year-old male
undergoes complete tumour removal by surgery (R0 resection). Tumour
recurrence is detected 1 year later. The probability of death, which is
roughly proportional to the area under the curve, increases dramatically
following tumour recurrence.
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ssurgery. The total treatment cost now amounts to US$ 510000
(17 US$ 30000). The lower drug price thus generates a 16% gross
profit increase for the pharmaceutical company, while at the same
time drug availability to patients is improved by 55%.
DISCUSSION
Here we introduce new general methodology, that employs
continuous hazard functions for analysis of survival data. To
estimate the continuous hazard functions, we have used Poisson
regression. This methodology means that short periods of time
are considered and that the person years within a period are
calculated, as well as the number of events. Each person can be
treated separately, and the number of events will typically be 0 or 1
for each short period. A maximum likelihood function could be
found and the parameters estimated by the same means (solving a
nonlinear system of equations) as parameters in a Cox regression,
or in a logistic regression. There are no restrictions on the number
of parameters, so in principle any continuous function can be
approximated. However, in practice the number of parameters has
to be quite small because of the limited size of available materials
for most cases.
The robustness of hazard function estimations, and the
calculated expected QALY gains, can be determined by simulation.
The hazard functions presented here permit simulation of events,
so that new estimations can be determined, and expected QALY
gains can be calculated repeatedly. We recommend simulations to
study the robustness of the model for each case. Such a sensitivity
analysis is more important for patients who are close to the cost-
benefit border.
Prospective QALY gains were calculated for 10-year periods
following adjuvant treatment of GIST with imatinib mesylate.
Available data to estimate the risk of death for GIST patients
following imatinib mesylate administration are limited. Clinical
practice nonetheless indicates that it is very close to normal.
Notably, none of the GIST patients who have undergone R0
tumour resection at our department have been diagnosed with
tumour recurrence following 1 year of treatment with imatinib
mesylate. The hazard ratio vs the general population is 1.08 (95%,
confidence interval 0.89–1.36). Accordingly, we substituted the
death hazard for GIST patients following treatment with imatinib
mesylate with the death hazard function of the general population
times 1.08 in our calculations. Moreover, no further reductions in
overall quality of life have been reported for GIST patients without
detected tumour recurrence. The expected QALY gain resulting
from imatinib mesylate administration is the difference between
the calculated QALY when imatinib mesylate is administered and
the expected QALY without administration of imatinib mesylate.
For the time being, we approximate the calculated QALY when
imatinib mesylate is administered with that of the general
population.
The methodology presented here is applicable for newly
diagnosed GIST patients as well as patients who underwent
surgery for GIST before imatinib mesylate was available. The pool
of GIST patients, for whom treatment is currently considered, is
thus made up of patients with newly detected GISTs as well as
patients who underwent surgery up to several years ago. Such
heterogeneity in the clinical situation is nevertheless typical for all
types of conditions for which more efficient treatment options are
expected to become available. A new generation of more selective
cancer drugs is beginning to reach the market, and the
methodology can easily be adapted to calculate the expected
QALY gain for each of these drugs.
At a fixed drug price the methodology can be used to decide
who should receive treatment, and who should not, depending on
health care legislation. Alternatively, the methodology can be
applied to negotiate optimal drug pricing and to investigate health
care intervention thresholds. Either way the methodology may
help reduce uncertainty in health care resource allocation, and
optimally renders all win situations that improve drug availability
to patients, make the most of public expenditure on drugs and
increase pharmaceutical company gross profits.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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